Statistical efficiency of outcome measures for secondary prevention trials in Alzheimer's disease: Evidence from the A4 trial
Alzheimer's & Dementia: Translational Research & Clinical Interventions · 2026-10 · 12 (4)
DOI: 10.1002/trc2.70344 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia: Translational Research & Clinical Interventions, online erschienen am 09.11.2026. Verfasst von Jasmin A Duehring und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biostatistics and Bioinformatics University of California San Diego La Jolla California USA. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Secondary prevention trials targeting preclinical Alzheimer's disease (AD) require clinical outcome assessments (COAs) that are sensitive to subtle decline that might be found in the cognitively unimpaired population typically enrolled in these trials. The recently completed Anti‐Amyloid Treatment in Asymptomatic Alzheimer's (A4) trial is an opportunity to explore the performance of commonly applied COAs in the preclinical AD population. METHODS The performance of COAs was compared using power calculations informed by data from the placebo arm of the A4 trial alone ( N = 583), and through a cross‐cohort analysis incorporating data from participants in the companion observational Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) study ( N = 538). Outcomes included the Preclinical Alzheimer's Cognitive Composite (PACC), the Clinical Dementia Rating Sum of Boxes (CDR‐SB), the Alzheimer's Disease Cooperative Study Activities of Daily Living Prevention Instrument (ADL‐PI), and the Cognitive Function Instrument (CFI). RESULTS The PACC and its component neuropsychological tests did not meaningfully decline over the first 168 weeks of the trial, compromising their utility as trial endpoints. In contrast, the CDR‐SB and the ADL‐PI declined monotonically. Based on the progression observed in A4 alone, a trial using the CDR‐SB endpoint would require a fraction of the participants required for a commonly used neuropsychological endpoint. DISCUSSION These findings help inform the selection of clinical endpoints for secondary prevention trials, and highlight potential limitations of cognitive performance tests in the earliest stages of AD. We found that practice effects on the PACC and its component tests were present despite the use of alternating test forms, reducing the effectiveness of these instruments in this population and motivating future exploration of the effectiveness of alternate clinical endpoints.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Biostatistics and Bioinformatics University of California San Diego La Jolla California USA.
- Department of Neurosciences University of California San Diego La Jolla California USA.
- Alzheimer's Disease Cooperative Study University of California San Diego, La Jolla, California La Jolla California USA.
- Shiley-Marcos Alzheimer's Disease Research Center University of California San Diego La Jolla California USA.
Förderung
- NIA NIH HHS
Zitieren
APA
Duehring, J. A., Feldman, H. H., Salmon, D. P., & Edland, S. D. (2026). Statistical efficiency of outcome measures for secondary prevention trials in Alzheimer's disease: Evidence from the A4 trial. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 12(4). https://doi.org/10.1002/trc2.70344
Vancouver
Duehring JA, Feldman HH, Salmon DP, Edland SD. Statistical efficiency of outcome measures for secondary prevention trials in Alzheimer's disease: Evidence from the A4 trial. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2026;12(4). doi:10.1002/trc2.70344
BibTeX
@article{Duehring2026,
author = {Duehring, Jasmin A and Feldman, Howard H and Salmon, David P and Edland, Steven D},
title = {Statistical efficiency of outcome measures for secondary prevention trials in Alzheimer's disease: Evidence from the A4 trial},
journal = {Alzheimer's & Dementia: Translational Research & Clinical Interventions},
year = {2026},
volume = {12},
number = {4},
doi = {10.1002/trc2.70344}
}
EUVIMED